Heron Therapeutics Inc ( (HRTX) ) has released its Q4 earnings. Here is a breakdown of the information Heron Therapeutics Inc presented to its investors.
Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on developing and commercializing therapeutic innovations to improve medical care, particularly in acute care and oncology sectors.
In its latest earnings report, Heron Therapeutics announced a significant financial turnaround with a GAAP net income of $3.6 million for the fourth quarter of 2024, marking a milestone achievement. The company also reported a 14% year-over-year increase in net revenue, reaching $144.2 million for the full year.
Key highlights from the report include the successful launch of the ZYNRELEF Vial Access Needle and a favorable court ruling upholding the validity of CINVANTI patents. Heron’s acute care segment showed impressive growth, with ZYNRELEF and APONVIE contributing significantly to the revenue increase. The company also expanded its promotional efforts for ZYNRELEF through a partnership with Crosslink Network, LLC, and secured separate payment status for ZYNRELEF under CMS policies until 2027.
Looking ahead, Heron Therapeutics is optimistic about 2025, with projected net revenue between $153 million and $163 million. The company aims to leverage its expanded product indications and strategic partnerships to drive further growth in the coming year.